Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents

Detalles Bibliográficos
Autor principal: Wang, Guangdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508469/
https://www.ncbi.nlm.nih.gov/pubmed/32968620
http://dx.doi.org/10.21037/tcr-20-2166
_version_ 1783585426710200320
author Wang, Guangdi
author_facet Wang, Guangdi
author_sort Wang, Guangdi
collection PubMed
description
format Online
Article
Text
id pubmed-7508469
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-75084692020-09-22 Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents Wang, Guangdi Transl Cancer Res Editorial Commentary AME Publishing Company 2020-08 /pmc/articles/PMC7508469/ /pubmed/32968620 http://dx.doi.org/10.21037/tcr-20-2166 Text en 2020 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Editorial Commentary
Wang, Guangdi
Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents
title Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents
title_full Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents
title_fullStr Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents
title_full_unstemmed Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents
title_short Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents
title_sort fulvestrant as a reference antiestrogen and estrogen receptor (er) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new er-targeting agents
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508469/
https://www.ncbi.nlm.nih.gov/pubmed/32968620
http://dx.doi.org/10.21037/tcr-20-2166
work_keys_str_mv AT wangguangdi fulvestrantasareferenceantiestrogenandestrogenreceptorerdegraderinpreclinicalstudiestreatmentdosageefficacyandimplicationsondevelopmentofnewertargetingagents

Ejemplares similares